AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
Phase 3
Completed
- Conditions
- Symptomatic Gastroesophageal Reflux Disease (sGERD)
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00626535
Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00626262
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
Phase 4
Completed
- Conditions
- HeartburnUpper Abdominal PainNauseaAcid Regurgitation
- Interventions
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT00625274
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2008-02-28
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00625495
Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA)
Phase 2
Completed
- Conditions
- Persistent or Permanent Non-valvular Atrial Fibrillation
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2012-03-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT00623779
- Locations
- 🇬🇧
Research Site, Newcastle Upon Tyne, United Kingdom
Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 165
- Registration Number
- NCT00623519
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients
Completed
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2016-10-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT00622323
- Locations
- 🇵🇭
Research Site, Taytay, Philippines
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT00621725
- Locations
- 🇳🇱
Research Site, Rotterdam, Netherlands
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT00621361
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Seroquel- Agitation Associated With Dementia
Phase 3
Completed
- Conditions
- Alzheimer's DiseaseVascular Dementia
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 333
- Registration Number
- NCT00621647
© Copyright 2025. All Rights Reserved by MedPath